Log in to search using one of your social media accounts:

This page shows you the latest items in this publication.

CardioFocus(R) Completes $20 Million Equity Financing
MARLBOROUGH, Mass., March 29, 2017 -- (Healthcare Sales & Marketing Network) -- CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announce... Devices, Cardiology, Venture Capital CardioFocus, HeartLight, Endoscopic Ablation, atrial fibrillation, ablation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2017 Category: Pharmaceuticals Source Type: news

Tyme Technologies Announces Two New Board of Director Appointments -- David Carberry and James Biehl
NEW YORK, March 29, 2017 -- (Healthcare Sales & Marketing Network) -- Tyme Technologies, Inc. (TYMI), a specialty biotechnology company developing cancer therapeutics targeted at multiple tumor types, today announced the addition of two new members to its ... Biopharmaceuticals, Oncology, Personnel Tyme Technologies, SM-88 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2017 Category: Pharmaceuticals Source Type: news

Tepha Inc. Subsidiary, Galatea Surgical, Announces Launch of GalaSHAPE(TM) 3D Surgical Scaffold
LEXINGTON, Mass., March 29, 2017 -- (Healthcare Sales & Marketing Network) -- Galatea Surgical, a wholly owned subsidiary of Tepha Inc., announced today the launch of its GalaSHAPE™ 3D Surgical Scaffold ("GalaSHAPE 3D") for use in aesthetic plas... Devices, Surgery, Product Launch Galatea Surgical, Tepha Inc, GalaSHAPE 3D, Surgical Scaffold (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2017 Category: Pharmaceuticals Source Type: news

Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon(R) Skin Descaler for Relief of Scaling Associated with Various Dermatoses
PETALUMA, Calif., March 29, 2017 -- (Healthcare Sales & Marketing Network) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of derm... Biopharmaceuticals, Dermatology, FDA Sonoma Pharmaceuticals, Loyon Skin Descaler, dermatoses (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only... Biopharmaceuticals, Neurology, FDA Genentech, Roche Group, OCREVUS, ocrelizumab, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2017 Category: Pharmaceuticals Source Type: news

Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Daniel M. Gallagher as chief legal officer. He will be joining the company on April 17, 20... Biopharmaceuticals, Personnel Mylan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis Dupixent will be available later this week to U.S. patients suffering from this chronic and... Biopharmaceuticals, Dermatology, FDA Regeneron Pharmaceuticals, Sanofi, Dupixent, dupilumab, Atopic Dermatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

Introducing PROMETHEUS(R) IBcause(TM): Convenient All-in-One Diagnostic Test for Persistent Diarrhea
SAN DIEGO, March 28, 2017 -- (Healthcare Sales & Marketing Network) -- Prometheus Laboratories Inc.—a Nestlé Health Science company—announces the launch of IBcause™, an all-in-one convenient test that evaluates a unique combination of 20 stool and ... Diagnostics, Gastroenterology, Product Launch Prometheus Laboratories, IBcause, diarrhea (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
ANN ARBOR, MI--(Healthcare Sales & Marketing Network) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced new appointments and promotions involving the compa... Biopharmaceuticals, Ophthalmology, Personnel ONL Therapeutics, retinal disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

Antiva Biosciences Closes $22 Million Series C Financing
SOUTH SAN FRANCISCO, Calif., March 28, 2017 -- (Healthcare Sales & Marketing Network) -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV... Biopharmaceuticals, Oncology, Venture Capital Antiva Biosciences, human papilloma virus, cervical cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

Nuvo Pharmaceuticals(TM) Enters into Pennsaid(R) 2% License Agreement with Sayre Therapeutics PVT Ltd. for India, Sri Lanka, Bangladesh and Nepal
MISSISSAUGA, ON, March 28, 2017 -- (Healthcare Sales & Marketing Network) - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, to... Biopharmaceuticals, Licensing Nuvo Pharmaceuticals, Sayre Therapeutics, Pennsaid (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

Akcea Therapeutics Announces Three Additions to Board of Directors
CAMBRIDGE, Mass., March 28, 2017 -- (Healthcare Sales & Marketing Network) -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (IONS), today announced three additions to the company's board of directors: Christopher Gabrieli, partner eme... Biopharmaceuticals, Cardiology, Personnel Akcea Therapeutics, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

Personal Genome Diagnostics' Expanded PlasmaSELECT(TM) 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology
BALTIMORE, March 28, 2017 -- (Healthcare Sales & Marketing Network) -- Personal Genome Diagnostics Inc. (PGDx) today announced the launch of its improved PlasmaSELECTTM 64 targeted panel for pan-cancer tumor profiling and assessment of microsatellite inst... Diagnostics, Oncology, Product Launch Personal Genome Diagnostics, PlasmaSELECT 64, genomic test (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2017 Category: Pharmaceuticals Source Type: news

Bracco Diagnostics Inc. announces the launch of the PROTOCO2L TOUCH(R) Colon Insufflator for use in CT Colonography procedures
MONROE TOWNSHIP, N.J., March 27, 2017 -- (Healthcare Sales & Marketing Network) -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announced the launch of its PROTOC... Devices, Radiology, Oncology, Product Launch Bracco Diagnostics, PROTOCO2L TOUCH, Colon Insufflator, Colonography (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2017 Category: Pharmaceuticals Source Type: news

Twist Bioscience Raises $33 Million
SAN FRANCISCO, March 27, 2017 -- (Healthcare Sales & Marketing Network) -- Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $33 million. To date, Twist ... Biopharmaceuticals, Diagnostics, Venture Capital Twist Bioscience, DNA synthesis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2017 Category: Pharmaceuticals Source Type: news

Bovie Medical Receives 510K Clearance for Its Cool-Coag(TM) Generator and Open Handpiece
CLEARWATER, Fla.--(Healthcare Sales & Marketing Network)--Bovie Medical (BVX) announced today that it has received 510K clearance from the FDA for a new J-Plasma® generator and handpiece that incorporate Cool-Coag™ technology. Cool-Coag™ is a new te... Devices, Surgery, FDA Bovie Medical, J-Plasma, Cool-Coag (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2017 Category: Pharmaceuticals Source Type: news

Bridge Medicines Appoints William J. Polvino, M.D., As Chief Executive Officer
NEW YORK, March 27, 2017 -- (Healthcare Sales & Marketing Network) -- Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the appointment of William J. Polvino, M.... Biopharmaceuticals, Personnel Bridge Medicines (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2017 Category: Pharmaceuticals Source Type: news

Dr. Reddy’s and Integra LifeSciences Enter into an Agreement to Market and Distribute DuraGen Plus(R) and Suturable DuraGen(R) Dural Regeneration in India
HYDERABAD, India--(Healthcare Sales & Marketing Network)--Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY, NYSE:RDY) and Integra LifeSciences Holdings Corporation (IART), a leading global medical technology company, announced today that they have... Devices, Regenerative Medicine, Neurosurgery, Distribution Dr. Reddy's Laboratories, Integra LifeSciences, DuraGen Plus, Dural Regeneration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2017 Category: Pharmaceuticals Source Type: news

Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HEMEL HEMPSTEAD, England, March 27, 2017 -- (Healthcare Sales & Marketing Network) --EUSA Pharma today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in favour of marketin... Biopharmaceuticals, Oncology, Regulatory EUSA Pharma, Dinutuximab beta, neuroblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2017 Category: Pharmaceuticals Source Type: news

Syneron Candela Announces CE Mark for CO2RE(R) Intima
CO2RE Intima Now First In-Office Laser Procedure CE Marked for the Treatment of Vaginal Atrophy and Rejuvenation IRVINE, California, March 27, 2017 -- (Healthcare Sales & Marketing Network) -- Syneron Medical Ltd. (ELOS), a leading global aesthetic dev... Devices, Regulatory Syneron Medical, Syneron Candela, CO2RE Intima, laser procedure, vaginal atrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2017 Category: Pharmaceuticals Source Type: news

Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
WESTLAKE VILLAGE, Calif., March 24, 2017 -- (Healthcare Sales & Marketing Network) -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company... Biopharmaceuticals, Dermatology, Personnel Sienna Biopharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 24, 2017 Category: Pharmaceuticals Source Type: news

Reata Pharmaceuticals, Inc. Appoints David Chapman as Vice President, Marketing
IRVING, Texas, March 24, 2017 -- (Healthcare Sales & Marketing Network) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”) today announced the appointment of David Chapman as Vice President, Marketing. Mr. Chapman joins the company with ov... Biopharmaceuticals, Personnel Reata Pharmaceuticals, bardoxolone, omaveloxolone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 24, 2017 Category: Pharmaceuticals Source Type: news

Surgery Without the Knife: Mirabilis Medical Announces European Approval for Non-Invasive Uterine Fibroid Treatment
BOTHELL, Wash., March 23, 2017 -- (Healthcare Sales & Marketing Network) -- Mirabilis Medical, a Seattle-area developer of advanced medical technology for non-invasive surgery, announced today CE Mark authorization for marketing of the Mirabilis System fo... Devices, Regulatory Mirabilis Medical, Mirabilis System, uterine fibroids (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 24, 2017 Category: Pharmaceuticals Source Type: news

FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
ROCKLAND, Mass. and NEW YORK, March 23, 2017 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (PFE) today announced that the US Food and Drug Ad... Biopharmaceuticals, Oncology, FDA, Product Launch EMD Serono, Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 24, 2017 Category: Pharmaceuticals Source Type: news

Revolutionary UroLift(R) System Launches in Ireland
Innovative UroLift System to Treat Enlarged Prostate ready for roll out to Irish patients nationally PLEASANTON, California, March 23, 2017 -- (Healthcare Sales & Marketing Network) -- NeoTract, Inc., announced today that the largest private health ins... Devices, Urology, Product Launch NeoTract, UroLift, Benign Prostatic Hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2017 Category: Pharmaceuticals Source Type: news

Tyme Appoints Ben Taylor as President and Chief Financial Officer
NEW YORK, March 23, 2017 -- (Healthcare Sales & Marketing Network) -- Tyme Technologies, Inc. (TYMI), (“Tyme” or “the Company”) a biotechnology company developing cancer therapeutics using metabolic pathways, today announced that Ben Taylor has been appoin... Biopharmaceuticals, Oncology, Personnel Tyme Technologies, SM-88 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2017 Category: Pharmaceuticals Source Type: news

410 Medical Closes $3.3 Million Initial Investment in Series A Financing
DURHAM, N.C., March 23, 2017 -- (Healthcare Sales & Marketing Network) -- 410 Medical, Inc., a medical device company focused on developing innovative technologies for the resuscitation of critically ill patients, today announced it has closed an initial ... Devices, Venture Capital 410 Medical, LifeFlow Rapid Infuser (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2017 Category: Pharmaceuticals Source Type: news

GE Healthcare to Offer a More Comfortable Mammography Experience
Advanced breast imaging platform, Senographe Pristina; expected to reshape the mammography experience with comfort, confidence and clarity for Patients, Technologists and Radiologists Purposefully Designed to help reduce pain, discomfort and anxiety for... Devices, Radiology, Product Launch GE Healthcare, Senographe Pristina, mammography, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2017 Category: Pharmaceuticals Source Type: news

Exact Imaging Introduces New FusionVu(TM) micro-US/MRI Fusion to Complement its ExactVu(TM) Micro-Ultrasound System for Prostate Imaging and Biopsy
FusionVu will be demonstrated at the EAU (European Association of Urology) 2017 Annual Congress in London, UK TORONTO and LONDON, UK, March 23, 2017 -- (Healthcare Sales & Marketing Network) - Exact Imaging (www.exactimaging.com), the world's leader in... Devices, Urology, Product Launch Exact Imaging, FusionVu, micro-US/MRI, micro-ultrasound (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2017 Category: Pharmaceuticals Source Type: news

New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
KING OF PRUSSIA, Pa., March 22, 2017 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase I... Biopharmaceuticals CSL Behring, COMPACT study, C1-INH, Hereditary Angioedema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2017 Category: Pharmaceuticals Source Type: news

Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
HOUSTON, TX--(Healthcare Sales & Marketing Network) - Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are base... Biopharmaceuticals, Oncology, FDA Moleculin Biotech, Annamycin, Acute Myeloid Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

BioStable Science and Engineering Announces FDA Clearance of the HAART(TM) 300 Aortic Annuloplasty Device
AUSTIN, Texas--(Healthcare Sales & Marketing Network)--BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device de... Devices, Cardiology, FDA BioStable Science & Engineering, HAART 300, Aortic Annuloplasty, aortic valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

Motus GI Appoints Samuel R. Nussbaum, M.D., to Board of Directors
NEW HOPE, PA--(Healthcare Sales & Marketing Network) - Motus GI, ("Motus GI" or the "Company"), a medical device company dedicated to improving colonoscopy outcomes and experiences, today announced that it has appointed Samuel R. Nussba... Devices, Gastroenterology, Oncology, Personnel Motus GI, colonoscopy, Pure-Vu (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
LOUISVILLE, CO--(Healthcare Sales & Marketing Network) - AntriaBio, Inc. ("AntriaBio or the "Company") (ANTB), a biopharmaceutical growth company specializing in the development of innovative drug therapies for patients with diabetes and met... Biopharmaceuticals, Endocrinology, Personnel AntriaBio, insulin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

Allergan Announces Availability of RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
DUBLIN, March 22, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) today announced the availability of RESTASIS MULTIDOSE™, which is the same preservative-free RESTASIS® formulation, but now offered in a multidose bottle. RESTASIS&... Biopharmaceuticals, Ophthalmology, Product Launch Allergan, RESTASIS, Cyclosporine, Chronic Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

George Bickerstaff Elected to Inovio’s Board of Directors
PLYMOUTH MEETING, Pa., March 21, 2017 -- (Healthcare Sales & Marketing Network) -- Inovio Pharmaceuticals, Inc. (INO) announced today the election of George Bickerstaff to its Board of Directors. Mr. Bickerstaff is an internationally recognized expert ... Biopharmaceuticals, Oncology, Personnel Inovio Pharmaceuticals, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2017 Category: Pharmaceuticals Source Type: news

SutroVax Announces Closing of $64M via Series B Financing
FOSTER CITY, Calif., March 21, 2017 -- (Healthcare Sales & Marketing Network) -- SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious dis... Biopharmaceuticals, Venture Capital, Personnel SutroVax, Xpress CF, vaccine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2017 Category: Pharmaceuticals Source Type: news

Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman
PARIS, March 21, 2017 -- (Healthcare Sales & Marketing Network) -- Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of ... Biopharmaceuticals, Devices, Ophthalmology, Personnel Eyevensys, EyeCET, electroporation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2017 Category: Pharmaceuticals Source Type: news

Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
MENLO PARK, Calif., March 20, 2017 -- (Healthcare Sales & Marketing Network) -- Forty Seven Inc., a clinical-stage immuno-oncology company announced today that Mark A. McCamish, M.D., Ph.D., will join the company on May 1 as President and CEO. Dr. McC... Biopharmaceuticals, Oncology, Personnel Forty Seven, CD47, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2017 Category: Pharmaceuticals Source Type: news

Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY(TM) ER
AUSTIN, Texas, March 20, 2017 -- (Healthcare Sales & Marketing Network) -- Pain Therapeutics, Inc. (PTIE) today announced positive regulatory guidance from a recent meeting with the U.S. Food and Drug Administration (FDA) regarding REMOXY (extended-release... Biopharmaceuticals, Drug Delivery, FDA Pain Therapeutics, REMOXY, extended-release, oxycodone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2017 Category: Pharmaceuticals Source Type: news

Trovita Health Science Announces FDA Marketing Clearance of New SAFE-T FEED(TM) Nutrition Delivery Device for Tube Feeding
PHILADELPHIA, March 20, 2017 -- (Healthcare Sales & Marketing Network) -- Trovita Health Science, an emerging life science company specializing in medical nutrition, announces U.S. Food and Drug Administration marketing authorization of the new SAFE-T FEE... Devices, FDA Trovita Health Science, SAFE-T FEED, enteral feeding (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news

JUVÉDERM VOLLURE(TM) XC Approved by U.S. FDA for Correction of Facial Wrinkles and Folds in Adults over the Age of 21
DUBLIN, March 20, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc, (AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉ... Devices, Dermatology, FDA Allergan, JUVÉDERM VOLLURE, JUVÉDERM, dermal filler (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody(TM) Therapeutics for the Treatment of Cancer and Other Diseases
NEW YORK & SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer... Biopharmaceuticals, Oncology Bristol-Myers Squibb, CytomX Therapeutics, Probody therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
INDIANAPOLIS, March 20, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemacic... Biopharmaceuticals, Oncology Eli Lilly, MONARCH 2, abemaciclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news

Piramal Pharma Solutions Names Stuart E. Needleman as Chief Commercial Officer
MUMBAI, March 20, 2017 -- (Healthcare Sales & Marketing Network) -- Piramal Pharma Solutions (PPS), a part of Piramal Enterprises Limited, announces the appointment of Stuart E. Needleman as its Chief Commercial Officer. PPS offers a unique end-to-end int... Biopharmaceuticals, Personnel Piramal Pharma Solutions (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news

Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively Patients in Study ... Biopharmaceuticals, Cardiology Amgen, Repatha, evolocumab, FOURIER trial (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news

Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed(R) Products
PALATINE, Ill., March 17, 2017 -- (Healthcare Sales & Marketing Network) -- Acura Pharmaceuticals, Inc. (ACUR) and MainPointe Pharmaceuticals, LLC today announced that they have entered into a License Agreement (the "Agreement") to have MainPoint... Biopharmaceuticals, Drug Delivery, Licensing Acura Pharmaceuticals, MainPointe Pharmaceuticals, Nexafed, pseudoephedrine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news

Toshiba Medical’s New Premium Cardiovascular Ultrasound Receives FDA Clearance
TUSTIN, Calif.--(Healthcare Sales & Marketing Network)--Cardiologists can now access the advanced ultrasound imaging technology needed for fast and confident diagnoses with Toshiba Medical’s Aplio™ i900. The newly FDA-cleared system is the latest addition ... Devices, FDA Toshiba America Medical Systems, Aplio i900, cardiovascular ultrasound (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news

New Study Shows Prevencio’s Simple Blood Test Determines Risk of Heart Attack, Stroke, or Cardiovascular Death
KIRKLAND, Wash.--(Healthcare Sales & Marketing Network)--Prevencio, Inc. today announces the presentation of data which demonstrate that a simple blood test is more accurate than commonly-used risk factors in determining whether a person will have a heart ... Diagnostics, Cardiology Prevencio, HART CVE, HART CAD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news

NICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife(TM) Battery Technology For Treatment Of Heart Failure
MARLBOROUGH, Mass., March 16, 2017 -- (Healthcare Sales & Marketing Network) -- Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (BSX) cardiac resy... Devices, Cardiology Boston Scientific, CRT-D, EnduraLife, cardiac resynchronization (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news